MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts
The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
MicroRNAs comprise a broad class of small non-coding RNAs that control expression of complementary target messenger RNAs. Dysregulation of microRNAs by several mechanisms has been described in various disease states including cardiac disease. Whereas previous studies of cardiac disease have focused on microRNAs that are primarily expressed in cardiomyocytes, the role of microRNAs expressed in other cell types of the heart is unclear. Here we show that microRNA-21 (miR-21, also known as Mirn21) regulates the ERK-MAP kinase signalling pathway in cardiac fibroblasts, which has impacts on global cardiac structure and function. miR-21 levels are increased selectively in fibroblasts of the failing heart, augmenting ERK-MAP kinase activity through inhibition of sprouty homologue 1 (Spry1). This mechanism regulates fibroblast survival and growth factor secretion, apparently controlling the extent of interstitial fibrosis and cardiac hypertrophy. In vivo silencing of miR-21 by a specific antagomir in a mouse pressure-overload-induced disease model reduces cardiac ERK-MAP kinase activity, inhibits interstitial fibrosis and attenuates cardiac dysfunction. These findings reveal that microRNAs can contribute to myocardial disease by an effect in cardiac fibroblasts. Our results validate miR-21 as a disease target in heart failure and establish the therapeutic efficacy of microRNA therapeutic intervention in a cardiovascular disease setting.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Epigenetic manipulation through long non-coding RNAs, miRNA modulators, and other oligonucleotides has yielded promising outcomes in experimental settings.162–165”
From Senescence-induced inflammation: an important player and key therapeutic target in atherosclerosis (2020) · cites this paper as [162]
Citations
Cites
1 retracted
Rockman, H. A., Ross, R. S., Harris, A. N., Knowlton, K. U., Steinhelper, M. E., Field, L. J., Ross, J., & Chien, K. R. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.18.8277 · Cited by 797
RetractedBartel (2004) · doi:10.1016/s0092-8674(04)00045-5 · Cited by 34,714
The functions of animal microRNAs
Ambros, V. (2004) · Nature · doi:10.1038/nature02871 · Cited by 10,728
Silencing of microRNAs in vivo with ‘antagomirs’
Krützfeldt, J., Rajewsky, N., Braich, R., Rajeev, K. G., Tuschl, T., Manoharan, M., & Stoffel, M. (2005) · Nature · doi:10.1038/nature04303 · Cited by 3,949
Self-citationA microRNA component of the p53 tumour suppressor network
He, L., He, X., Lim, L. P., de Stanchina, E., Xuan, Z., Liang, Y., Xue, W., Zender, L., Magnus, J., Ridzon, D., et al. (2007) · Nature · doi:10.1038/nature05939 · Cited by 2,692
A synthetic inhibitor of the mitogen-activated protein kinase cascade.
Dudley, D. T., Pang, L., Decker, S. J., Bridges, A. J., & Saltiel, A. R. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.17.7686 · Cited by 2,679
MicroRNA-133 controls cardiac hypertrophy
Carè, A., Catalucci, D., Felicetti, F., Bonci, D., Addario, A., Gallo, P., Bang, M.-L., Segnalini, P., Gu, Y., Dalton, N. D., et al. (2007) · Nature Medicine · doi:10.1038/nm1582 · Cited by 1,776
Control of Stress-Dependent Cardiac Growth and Gene Expression by a MicroRNA
van Rooij, E., Sutherland, L. B., Qi, X., Richardson, J. A., Hill, J., & Olson, E. N. (2007) · Science · doi:10.1126/science.1139089 · Cited by 1,657
Dysregulation of Cardiogenesis, Cardiac Conduction, and Cell Cycle in Mice Lacking miRNA-1-2
Zhao, Y., Ransom, J. F., Li, A., Vedantham, V., von Drehle, M., Muth, A. N., Tsuchihashi, T., McManus, M. T., Schwartz, R. J., & Srivastava, D. (2007) · Cell · doi:10.1016/j.cell.2007.03.030 · Cited by 1,429
Yang, B., Lin, H., Xiao, J., Lu, Y., Luo, X., Li, B., Zhang, Y., Xu, C., Bai, Y., Wang, H., et al. (2007) · Nature Medicine · doi:10.1038/nm1569 · Cited by 1,138
Cited by
Items 701–800 of 1,006
Bertero, T., Cottrill, K. A., Annis, S., Bhat, B., Gochuico, B. R., Osorio, J. C., Rosas, I., Haley, K. J., Corey, K. E., Chung, R. T., et al. (2015) · Scientific Reports · doi:10.1038/srep18277 · Cited by 68
Han, X., Wang, Y., Zhang, X., Qin, Y., Qu, B., Wu, L., Ma, J., Zhou, Z., Qian, J., Dai, M., et al. (2016) · Arthritis & Rheumatology · doi:10.1002/art.39725 · Cited by 67
“Recent studies suggest that modulation of miRNA expression by administration of oligonucleotides to mice could control disease progression (46,47).”
Chen, P., Xu, W., Luo, Y., Zhang, Y., He, Y., Yang, S., & Yuan, Z. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s118366 · Cited by 65
“Mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) signal pathway was highly conserved in eukaryotes, and its abnormal expression was closely related to human diseases.(14,15) Thus, we infer that miR-543 is a breast cancer suppressor that inhibits breast cancer cells, progression throu…”
Effects of Physical Exercise on the Expression of MicroRNAs: A Systematic Review
da Silva, F. C., Iop, R. D. R., Andrade, A., Costa, V. P., Filho, P. J. B. G., & da Silva, R. (2019) · The Journal of Strength and Conditioning Research · doi:10.1519/jsc.0000000000003103 · Cited by 71
“The miR-21 is linked to vascular inflammation and skeletal and cardiac muscle function (88,92).”
BackgroundCurrent and emerging drug targets in heart failure treatment
Ghionzoli, N., Gentile, F., Franco, A. D., Castiglione, V., Aimo, A., Giannoni, A., Burchielli, S., Cameli, M., Emdin, M., & Vergaro, G. (2021) · Heart Failure Reviews · doi:10.1007/s10741-021-10137-2 · Cited by 72
Role of interleukin-6 in regulation of immune responses to remodeling after myocardial infarction
Huang, M., Du, Y., Xiang, M., & Wang, J. (2014) · Heart Failure Reviews · doi:10.1007/s10741-014-9431-1 · Cited by 77
“And very recently it was shown that inhibition of a fibroblast-selective miRNA ameliorated cardiac fibrosis, hypertrophy, and dysfunction, suggesting that fibroblasts play a detrimental role in cardiac remodeling [112].”
BackgroundMicroRNA Expression Changes after Atrial Fibrillation Catheter Ablation
Sardu, C., Santamaria, M., Paolisso, G., & Marfella, R. (2015) · Pharmacogenomics · doi:10.2217/pgs.15.117 · Cited by 67
Shah, P. M., Bristow, M. R., & Port, J. D. (2017) · Current Heart Failure Reports · doi:10.1007/s11897-017-0362-8 · Cited by 66
miR-21-5p regulates mitochondrial respiration and lipid content in H9C2 cells
Nasci, V. L., Chuppa, S. L., Griswold, L., Goodreau, K. L., Dash, R. K., & Kriegel, A. J. (2019) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00538.2017 · Cited by 67
Sun, J., Shi, L., Xiao, T., Xue, J., Li, J., Wang, P., Wu, L. Y., Dai, X., Ni, X., & Liu, Q. (2020) · Chemosphere · doi:10.1016/j.chemosphere.2020.129177 · Cited by 66
Platelet-Derived MicroRNAs Regulate Cardiac Remodeling After Myocardial Ischemia
Schütte, J. P., Manke, M.-C., Hemmen, K., Münzer, P., Schörg, B. F., Ramos, G. C., Pogoda, M., Dicenta, V., Hoffmann, S. H. L., Pinnecker, J., et al. (2023) · Circulation Research · doi:10.1161/circresaha.122.322459 · Cited by 72
Qiao, S., Olson, J. M., Paterson, M., Yan, Y., Zaja, I., Liu, Y., Riess, M. L., Kersten, J. R., Liang, M., Warltier, D. C., et al. (2015) · Anesthesiology · doi:10.1097/aln.0000000000000807 · Cited by 63
MicroRNAs and atherosclerosis: New actors for an old movie
Santovito, D., Mezzetti, A., & Cipollone, F. (2012) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2012.03.007 · Cited by 66
“Other miRNAs involved in collagen synthesis and fibrosis are miR-21 [48], miR-29b [70] and miR-19 [71].”
BackgroundLi, H., Zhao, X., Shan, H., & Liang, H. (2016) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2016.06.010 · Cited by 72
O’Sullivan, M. P., Looney, A.-M., Moloney, G. M., Finder, M., Hallberg, B., Clarke, G. A., Boylan, G. B., & Murray, D. M. (2018) · JAMA Neurology · doi:10.1001/jamaneurol.2018.4182 · Cited by 71
van der Voorn, S. M., te Riele, A. S. J. M., Basso, C., Calkins, H., Remme, C. A., & van Veen, T. A. B. (2020) · Cardiovascular Research · doi:10.1093/cvr/cvaa084 · Cited by 62
“In contrast to the effect of miR-21 on fibroblasts, it apparently does not modify cardiomyocyte function or morphology.(101) A second miRNA involved in regu-”
BackgroundHu, Y., Matkovich, S. J., Hecker, P. I., Zhang, Y., Edwards, J. R., & Dorn, G. W. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1214996109 · Cited by 63
“Hypertrophy-regulated microRNAs include miR-21, previously implicated in myocardial hypertrophy remodeling, fibrosis, and cytoprotection (11, 12); miR-127, which regulates mitochondrial bioenergetics (13); and miR-199, previously linked to cardiac hypertrophy signaling through calcineurin/ NFAT (14).”
BackgroundMicroRNA Implications across Neurodevelopment and Neuropathology
Martino, S., di Girolamo, I., Orlacchio, A., Datti, A., & Orlacchio, A. (2009) · BioMed Research International · doi:10.1155/2009/654346 · Cited by 61
“In this regard, treatment of a mouse model of heart disease with an antagomir against miR-21 prevented heart failure [181], and antagomirs to target glioma angiogenesis has recently been proposed [182].”
BackgroundMartinelli, N. C., Cohen, C. R., dos Santos, K. G., Castro, M. A. A., Biolo, A., Frick, L. M., Silvello, D., Lopes, A. G., Schneider, S., Andrades, M. É., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0093271 · Cited by 67
“associated with pathological cardiomyocyte growth, including miR-21, -195 and -499 [25,26,27,28,29,30].”
BackgroundHu, Y., Zhang, L., Wu, X., Hou, L., Li, Z., Ju, J., Li, Q., Qin, W., Li, J., Zhang, Q., et al. (2016) · Toxicology Letters · doi:10.1016/j.toxlet.2016.03.008 · Cited by 68
Gene expression profiling of acute type A aortic dissection combined with in vitro assessment†
Kimura, N., Futamura, K., Arakawa, M., Okada, N., Emrich, F. C., Okamura, H., 佐藤哲也, Shudo, Y., Koyano, T. K., Yamaguchi, A., et al. (2017) · European Journal of Cardio-Thoracic Surgery · doi:10.1093/ejcts/ezx095 · Cited by 62
“miR-21 regulates the ERK-MAP kinase signalling pathway in cardiac fibroblasts and its up-regulation induces cardiac fibrosis [24].”
BackgroundHyperglycemia-induced cardiac contractile dysfunction in the diabetic heart
Singh, R. M., Waqar, T., Howarth, F. C., Adeghate, E. A., Bidasee, K. R., & Singh, J. (2017) · Heart Failure Reviews · doi:10.1007/s10741-017-9663-y · Cited by 73
“The noncoding RNA, miR-223 was found to be associated with regulation of GLUT4 expression in adult cardiomyocytes [185] while data from experimental studies underscore the contribution of miR-21 in stimulating MAP kinase signaling in mouse fibroblasts, consequently promoting fibrosis and contractility alterations as f…”
Gu, H., Liu, Z., Li, Y., Xie, Y., Yao, J., Zhu, Y., Xu, J., Dai, Q., Zhong, C., Zhu, H., et al. (2018) · Frontiers in Physiology · doi:10.3389/fphys.2018.00348 · Cited by 63
“Antagonizing miR-21 inhibits interstitial fibrosis and attenuates cardiac dysfunction in a mouse model of heart failure (Thum et al., 2008).”
BackgroundAbdolmohammadi‐Vahid, S., Ghaebi, M., Ahmadi, M., Nouri, M., Danaii, S., Maleki, L. A., Ardehaie, R. M., Yousefi, B., Hakimi, P., Hojjat‐Farsangi, M., et al. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.27290 · Cited by 67
“According to recent investigations, miRNAs are involved in various disease and may be used as prognostic and diagnostic biomarkers (J. Lu et al., 2005; Slack & Weidhaas, 2008; Thum et al., 2008).”
BackgroundYu, C., Qian, L., Uttamchandani, M., Li, L., & Yao, S. Q. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201504913 · Cited by 62
Ciccarelli, M., Dawson, D. K., Falcão‐Pires, I., Giacca, M., Hamdani, N., Heymans, S. R. B., Hooghiemstra, A. M., Leeuwis, A. E., Hermkens, D. M. A., Tocchetti, C. G., et al. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab009 · Cited by 68
“ncRNAs-based intervention could also be used to achieve anti-fibrotic or anti-inflammatory effects.(29,175,176) Interestingly, the liver-specific”
BackgroundMethodSelf-citationKuster, D. W. D., Mulders, J., ten Cate, F. J., Michels, M., dos Remedios, C. G., Martins, P. A. D. C., van der Velden, J., & Oudejans, C. B. M. (2013) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2013.09.012 · Cited by 62
“Although miRNA-21, a miRNA predominantly expressed in fibroblasts and a contributor to cardiac remodeling [33] was unchanged between HCM and donor groups (fold change 1.”
BackgroundNovel Insights into miRNA in Lung and Heart Inflammatory Diseases
Kishore, A., Borucka, J., Petřková, J., & Petřek, M. (2014) · Mediators of Inflammation · doi:10.1155/2014/259131 · Cited by 75
“Application of antagomirs/anti-miRs in the animal model has shown few significant promising results [84, 130, 184, 188].”
BackgroundNew Insights into the Pathogenesis and Treatment of Idiopathic Pulmonary Fibrosis
Ding, Q., Luckhardt, T., Hecker, L., Zhou, Y., Liu, G., Antony, V. B., deAndrade, J. A., & Thannickal, V. J. (2011) · Drugs · doi:10.2165/11591490-000000000-00000 · Cited by 69
“expression of miRNAs has been linked to fibrotic diseases in various organs.([105-109]) In the heart, miR-133 expression is reduced during nicotineinduced atrial fibrosis, and exogenous miR-133 expression in cultured atrial fibroblasts decreases levels of TGF-b1 and TGF-bRII, and production of collagen.”
BackgroundMicroRNAs in common diseases and potential therapeutic applications
Tsai, L. M., & Yu, D. (2009) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.2009.05269.x · Cited by 68
“Clinically, silencing miR-21 attenuates cardiac dysfunction and shows therapeutic efficacy.(33)”
BackgroundCirculating biomarkers in pulmonary arterial hypertension: Update and future direction
Pezzuto, B., Badagliacca, R., Poscia, R., Ghio, S., D’Alto, M., Vitulo, P., Mulè, M., Albera, C., Volterrani, M., Fedele, F., et al. (2014) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2014.12.005 · Cited by 66
Expression and Function of MicroRNAs in Heart Disease
Ikeda, S., & Pu, W. T. (2010) · Current Drug Targets · doi:10.2174/138945010791591304 · Cited by 69
miR-483-3p regulates hyperglycaemia-induced cardiomyocyte apoptosis in transgenic mice
Qiao, Y., Zhao, Y., Liu, Y., Ma, N., Wang, C., Zou, J., Liu, Z., Zhou, Z., Han, D. H., He, J., et al. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.06.051 · Cited by 63
Koledova, Z. S., Zhang, X. M., Streuli, C. H., Clarke, R. B., Klein, O. D., Werb, Z., & Lu, P. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1611532113 · Cited by 62
“Mice carrying the Spry1 (31) allele and Spry2-GOF mice (46) were provided by M.”
BackgroundMethodThe Role and Molecular Mechanism of Non-Coding RNAs in Pathological Cardiac Remodeling
Gao, J., Xu, W., Wang, J., Wang, K., & Li, P. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18030608 · Cited by 64
Pathophysiological understanding of HFpEF: microRNAs as part of the puzzle
Rech, M., Aizpurua, A. B., van Empel, V. P. M., van Bilsen, M., & Schroen, B. L. M. (2018) · Cardiovascular Research · doi:10.1093/cvr/cvy049 · Cited by 70
“In vivo inhibition of miR-21 prevents the development of pressure overloadinduced cardiac interstitial fibrosis and cardiac dysfunction.(75)”
BackgroundMohammadzadeh, N., Lunde, I. G., Andenæs, K., Strand, M. E., Aronsen, J. M., Skrbic, B., Marstein, H. S., Bandlien, C., Nygård, S., Gorham, J., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-45651-9 · Cited by 63
Cresci, S., Pereira, N. L., Ahmad, F., Byku, M., Fuentes, L. D. L., Lanfear, D. E., Reilly, C. M., OWENS, A. T., & Wolf, M. J. (2019) · Circulation Genomic and Precision Medicine · doi:10.1161/hcg.0000000000000058 · Cited by 64
Next RNA Therapeutics: The Mine of Non-Coding
Garbo, S., Maione, R., Tripodi, M., & Battistelli, C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23137471 · Cited by 62
Investigational drugs targeting cardiac fibrosis
Roubille, F., Busseuil, D., Merlet, N., Kritikou, E. A., Rhéaume, É., & Tardif, J. (2013) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.2013.839942 · Cited by 68
Notch Regulation of Tumor Angiogenesis
Bridges, E., Oon, C. E., & Harris, A. L. (2011) · Future Oncology · doi:10.2217/fon.11.20 · Cited by 65
“While little is known of miRNA interactions with the Notch pathway [127,128], studies have demonstrated that miRNAs could regulate other signaling pathways such as WNT, TGFb and the AKT and MAPK pathways [129–140].”
BackgroundHaider, K. H., Idris, N. M., Kim, H. W., Ahmed, R. P. H., Shujia, J., & Ashraf, M. (2010) · Cardiovascular Research · doi:10.1093/cvr/cvq151 · Cited by 61
“fashion.(5) The pro-survival and anti-apoptotic activity of miR-21 was also linked with multiple transcription factors including signal transducers and Stat3.”
BackgroundSmall changes can make a big difference — MicroRNA regulation of cardiac hypertrophy
Gladka, M. M., Martins, P. A. D. C., & Windt, L. J. D. (2011) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2011.09.015 · Cited by 69
“[51], failed to block the remodeling cardiac response to stress conditions, suggesting that the chemical nature of oligonucleotides used for miR-21 silencing approach in vivo has a significant impact on the phenotypic outcome and therapeutic benefit [56].”
BackgroundLi, N., Wang, Z., Gao, F., Lei, Y., & Li, Z. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.15221 · Cited by 61
Wronska, A. (2022) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.121.001152 · Cited by 66
Dippold, R. P., Vadigepalli, R., Gonye, G. E., & Hoek, J. B. (2012) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00019.2012 · Cited by 61
MicroRNAs in Cardiac Apoptosis
Li, P. (2010) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-010-9175-9 · Cited by 63
“miR-21 can regulate the ERK-MAP kinase signaling pathway in cardiac fibroblasts, which has impacts on global cardiac structure and function [60].”
BackgroundMolecular mechanisms of the cartilage-specific microRNA-140 in osteoarthritis
Zhang, R., Ma, J., & Yao, J. (2013) · Inflammation Research · doi:10.1007/s00011-013-0654-8 · Cited by 66
“MiRNAs have been implicated in the process of development and pathogenesis of diseases, such as cancer and cardiovascular diseases [14, 15], and tissue-specific miRNA functional studies in mice have revealed both pathogenic and protective functions [16].”
BackgroundKnöll, R., Iaccarino, G., Tarone, G., Hilfiker‐Kleiner, D., Bauersachs, J. K., Leite-Moreira, A. F., Sugden, P. H., & Balligand, J. (2011) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfr071 · Cited by 62
“In this context, the fibroblasts (which are responsible for ECM deposition) may be important regulators of the cardiac myocyte hypertrophic response.(11,12)”
BackgroundSelf-citationGene therapy for ischemic heart disease
Hinkel, R., Trenkwalder, T., & Kupatt, C. (2011) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2011.570749 · Cited by 68
“Inhibition of miR21 via specific antagomirs decreased cardiac hypertrophy and fibrosis over inhibition of sprout homolous 1 [79].”
BackgroundEpigenetic and Transcriptomic Regulation of Lung Repair during Recovery from Influenza Infection
Pociask, D. A., Robinson, K. M., Chen, K., McHugh, K. J., Clay, M. E., Huang, G. T.-W., Benos, P. V., Janssen-Heininger, Y. M. W., Kolls, J. K., Anathy, V., et al. (2017) · American Journal Of Pathology · doi:10.1016/j.ajpath.2016.12.012 · Cited by 61
“miR-21 was demonstrated to promotefibroblast survival, and its inhibition decreased scarring in a mouse model of myocardial infarction.(42,43) Inhibition of miR-21 also attenuated bleomycininduced fibrosis.”
BackgroundVarzideh, F., Kansakar, U., Donkor, K., Wilson, S. M., Jankauskas, S. S., Mone, P., Wang, X., Lombardi, A., & Santulli, G. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.863238 · Cited by 59
Next Steps in Cardiovascular Disease Genomic Research—Sequencing, Epigenetics, and Transcriptomics
Schnabel, R. B., Baccarelli, A., Lin, H., Ellinor, P. T., & Benjamin, E. J. (2012) · Clinical Chemistry · doi:10.1373/clinchem.2011.170423 · Cited by 65
“Antagomirs targeted at miR-21 reduced remodeling as a response to pressure overload(84), and miR-23a knockdown in mice prevented cardiac hypertrophy(54).”
BackgroundRole of MicroRNAs in Cardiovascular Disease: Therapeutic Challenges and Potentials
Port, J. D., & Sucharov, C. C. (2010) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0b013e3181f605b6 · Cited by 68
“miR-21 also targets sprouty homolog 1 (SPRY1), a negative regulator of the extracellular signaling receptor kinase-MAP kinase signaling pathway.(57) Activation of the mitogen-activated protein kinase pathway and increased matrix metalloproteinase 2 expression in fibroblasts are thought to increase interstitial fibrosi…”
BackgroundInfluentialShielding the messenger (RNA): microRNA-based anticancer therapies
Sotillo, E., & Thomas‐Tikhonenko, A. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.04.006 · Cited by 65
“The latter problem is illustrated by studies where inhibition of cardiac hypertrophy and fibrosis had been observed in mice using a miR-21 antagomir (Thum et al. 2008) but subsequent genetic ablation of the miR-21 gene failed to elicit a similar cardiac phenotype (Patrick et al. 2010).”
BackgroundMicroRNAs in Stem Cell Function and Regenerative Therapy of the Heart
Seeger, F. H., Zeiher, A. M., & Dimmeler, S. (2013) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.113.300138 · Cited by 59
“Subsequent studies blocked miR-21 by antagomirs and reported that this enhanced cardiac function and prevents cardiac fibrosis.(69) However, genetic deletion of miR-21 or blocking of miR-21 with shorter locked nucleic acid-based anti-miRs had no effect in other studies.”
BackgroundThe physiological impact of microRNA gene regulation in the retina
Sundermeier, T. R., & Palczewski, K. (2012) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-012-0976-7 · Cited by 59
“Indeed the number of published reports dealing with miRNA gene regulation has increased by greater than tenfold over the past 6 years, bolstered by discovery of miRNAs involved in a myriad of human diseases together with substantial progress toward targeting miRNAs for therapeutic intervention [35–39].”
BackgroundRole of microRNAs in cardiac hypertrophy and heart failure
Wang, N., Zhou, Z., Liao, X., & Zhang, T. (2009) · IUBMB Life · doi:10.1002/iub.204 · Cited by 66
Control of MicroRNA Expression as a New Way for Resveratrol To Deliver Its Beneficial Effects
Lançon, A., Kaminski, J., Tili, E., Michaille, J., & Latruffe, N. (2012) · Journal of Agricultural and Food Chemistry · doi:10.1021/jf301479v · Cited by 60
miTALOS: Analyzing the tissue-specific regulation of signaling pathways by human and mouse microRNAs
Kowarsch, A., Preusse, M., Marr, C., & Theis, F. J. (2011) · RNA · doi:10.1261/rna.2474511 · Cited by 60
“…order to predict the impact of a specific miRNA on a signaling pathway, we have to understand the principles of miRNA-mediated regulation and analyze the target patterns to predict an miRNA pathway interaction from a functional perspective (Cui et al. 2006; Tsang et al. 2007; Kowarsch et al. 2010).”
BackgroundCunnington, R. H., Wang, B., Ghavami, S., Bathe, K. L., Rattan, S. G., & Dixon, I. (2010) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00050.2010 · Cited by 66
New Directions in Antiarrhythmic Drug Therapy for Atrial Fibrillation
Heijman, J., Voigt, N., & Dobrev, D. (2012) · Future Cardiology · doi:10.2217/fca.12.78 · Cited by 62
“Similarly, Thum and colleagues have shown that an antagomir against miR-21 was able to halt the development of left ventricular hypertrophy and reduce ventricular fibrosis in mice subjected to transverse aortic constriction [120].”
BackgroundBasigin Promotes Cardiac Fibrosis and Failure in Response to Chronic Pressure Overload in Mice
Suzuki, K., Satoh, K., Ikeda, S., Sunamura, S., Otsuki, T., Satoh, T., Kikuchi, N., Omura, J., Kurosawa, R., Nogi, M., et al. (2016) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.115.306686 · Cited by 58
Epigenetics in heart failure phenotypes
Berezin, A. Е. (2016) · BBA Clinical · doi:10.1016/j.bbacli.2016.05.005 · Cited by 61
Sun, N.-N., Yu, C., Pan, M., Zhang, Y., Zheng, B., Yang, Q., Zheng, Z., & Meng, Y. (2017) · Scientific Reports · doi:10.1038/s41598-017-13305-3 · Cited by 61
CITED4 Protects Against Adverse Remodeling in Response to Physiological and Pathological Stress
Lerchenmüller, C., Rabolli, C. P., Yeri, A., Kitchen, R. R., Salvador, A. M., Liu, L. X., Ziegler, O., Danielson, K., Platt, C., Shah, R. V., et al. (2020) · Circulation Research · doi:10.1161/circresaha.119.315881 · Cited by 69
MicroRNAs regulating superoxide dismutase 2 are new circulating biomarkers of heart failure
Dubois‐Deruy, E., Cuvelliez, M., Fiedler, J., Charrier, H., Mulder, P. G. H., Hebbar, E., Pfanne, A., Beseme, O., Chwastyniak, M., Amouyel, P., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-15011-6 · Cited by 57
Self-citationHuang, Y., Xie, Y., Abel, P. W., Wei, P., Plowman, J. N., Toews, M. L., Strah, H. M., Siddique, A., Bailey, K. L., & Tu, Y. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114172 · Cited by 64
Li, S., Ran, Y., Zhang, D., Li, S., & Zhu, D. (2014) · Journal of Cellular Biochemistry · doi:10.1002/jcb.24771 · Cited by 61
Non-Coding RNAs: The “Dark Matter” of Cardiovascular Pathophysiology
Iaconetti, C., Gareri, C., Polimeni, A., & Indolfi, C. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms141019987 · Cited by 68
“Another microRNA induced by TGF-β and dysregulated in fibroblasts, including in cardiac fibroblasts, in multiple types of stress, is miR-21 [144,145].”
BackgroundIntercellular Communication Lessons in Heart Failure
Bang, C., Antoniades, C. A., Antonopoulos, A. S., Eriksson, U., Franssen, C., Hamdani, N., Lehmann, L., Moessinger, C., Mongillo, M., Muhl, L., et al. (2015) · European Journal of Heart Failure · doi:10.1002/ejhf.399 · Cited by 62
Self-citationHe, W., Huang, H., Xie, Q., Wang, Z., Fan, Y., Kong, B., Huang, D., & Xiao, Y. (2015) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248415616188 · Cited by 58
“and failure.(14) Upregulation of miR-155 has been implicated in inflammatory diseases, including rheumatoid arthritis,(15) multiple sclerosis,(16) and heart disease.”
BackgroundmicroRNA profiling in atherosclerosis, diabetes, and migraine
Tana, C., Giamberardino, M. A., & Cipollone, F. (2016) · Annals of Medicine · doi:10.1080/07853890.2016.1226515 · Cited by 62
“A reduction of cardiac dysfunction and interstitial fibrosis was obtained also by suppressing miR-21 with a specific antagomir in mouse models (107).”
BackgroundMechanisms of Cardiomyocyte Proliferation and Differentiation in Development and Regeneration
Yester, J., & Kühn, B. (2017) · Current Cardiology Reports · doi:10.1007/s11886-017-0826-1 · Cited by 63
Dai, J., Chen, W., Lin, Y., Wang, S., Guo, X., & Zhang, Q. (2017) · International Journal of Biological Sciences · doi:10.7150/ijbs.19868 · Cited by 57
“It has been demonstrated that miR-21 plays an important role in tumors and heart disease [35-40].”
BackgroundZhang, Y., Lu, Y., Machuki, J. O., Ge, L., Qian, Y., Chen, L., Hu, X., Li, F., Wei, H., Zhang, C., et al. (2018) · BioMed Research International · doi:10.1155/2018/8730593 · Cited by 60
“In myocardial tissues, miR-21 targets endogenous mitogen activated protease inhibitor Spry1 and activates the ERK-MAPK pathway, thus inhibiting apoptosis of CFs and activating myocardial fibrosis [34].”
BackgroundDeciphering Non-coding RNAs in Cardiovascular Health and Disease
Das, A., Samidurai, A., & Salloum, F. N. (2018) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2018.00073 · Cited by 60
“Multiple studies reported that increased expression of miR-21 in fibroblasts of the failing heart induces the extent of interstitial fibrosis and cardiac hypertrophy by augmenting ERK–MAP kinase activity via inhibition of sprouty homolog 1 (Spry1) (91) or enhancing matrix metalloproteinase-2 (MMP-2) via PTEN (phosphat…”
BackgroundHamdani, N., Costantino, S., Mügge, A., Lebeche, D., Tschöpe, C., Thum, T., & Paneni, F. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab197 · Cited by 59
Self-citationPeikert, A., Fontana, M., Solomon, S. D., & Thum, T. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf524 · Cited by 74
“154 154 Like miR-21, miR-29 is prominently expressed in cardiac myocytes, exerting an important role in cardiac remodelling by promoting pathologic hypertrophy of cardiac myocytes, whereas a global genetic deletion and a specific inhibition of miR-29 reduced cardiac hypertrophy and fibrosis and…”
Self-citationRamani, R. N., Vela, D. C., Segura, A., McNamara, D. M., Lemster, B. H., Samarendra, V., Kormos, R. L., Toyoda, Y., Bermudez, C. A., Frazier, O. H., et al. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.08.041 · Cited by 57
“Several reports have identified specific miRs that modulate pathologic processes relevant to heart failure; hypertrophy (16,18,19,23), cell death (28), fibrosis (20,29), vascular proliferation (30), and arrhythmias (17,31).”
BackgroundSmall and long non-coding RNAs in cardiac homeostasis and regeneration
Ounzain, S., Crippa, S., & Pedrazzini, T. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2012.08.010 · Cited by 65
Pathophysiology of translational regulation by microRNAs in multiple sclerosis
Junker, A. (2011) · FEBS Letters · doi:10.1016/j.febslet.2011.03.052 · Cited by 58
Ooi, J. Y. Y., Bernardo, B. C., Singla, S., Patterson, N. L., Lin, R. C. Y., & McMullen, J. R. (2016) · RNA Biology · doi:10.1080/15476286.2016.1181251 · Cited by 56
“In vivo silencing inhibited cardiac fibrosis and attenuated cardiac dysfunction in a mouse pressure overload model.(31) In an acute ischemia preconditioning rat model, miR-21 was shown to provide protection (miR-21 was inhibited with an antagomiR).”
BackgroundProfiling of differentially expressed microRNAs in arrhythmogenic right ventricular cardiomyopathy
Zhang, H., Liu, S., Dong, T., Yang, J., Xie, Y., Wu, Y., Kang, K., Hu, S., Gou, D., & Wei, Y. (2016) · Scientific Reports · doi:10.1038/srep28101 · Cited by 64
Azimzadeh, O., Azizova, T. V., Merl‐Pham, J., Subramanian, V., Bakshi, M. V., Moseeva, M. B., Zubkova, O. V., Hauck, S. M., Anastasov, N., Atkinson, M. J., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10424 · Cited by 56
“Increased levels of mir-21 in heart failure and ischemia have been reported [19, 38, 39].”
BackgroundMicroRNA-31 promotes adverse cardiac remodeling and dysfunction in ischemic heart disease
Martinez, E. C., Lilyanna, S., Wang, P., Vardy, L. A., Jiang, X., Armugam, A., Jeyaseelan, K., & Richards, M. (2017) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2017.08.013 · Cited by 58
Role of miRNAs on the Pathophysiology of Cardiovascular Diseases
Pereira‐Silva, D. C., Carneiro, F. D., Almeida, K. C. D., & Fernandes‐Santos, C. (2018) · Arquivos Brasileiros de Cardiologia · doi:10.5935/abc.20180215 · Cited by 72
Stochastic RNA Walkers for Intracellular MicroRNA Imaging
Xiao, M., Wang, X., Li, L., & Pei, H. (2019) · Analytical Chemistry · doi:10.1021/acs.analchem.9b02265 · Cited by 56
Nonaka, C. K. V., Macêdo, C. T., Cavalcante, B. R. R., de Alcântara, A. C., Silva, D. N., Bezerra, M. D. R., Caria, A. C. I., Tavora, F. R. F., Neto, J. D. D. S., Noya-Rabelo, M., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20164064 · Cited by 67
Exosomes: From Potential Culprits to New Therapeutic Promise in the Setting of Cardiac Fibrosis
Tikhomirov, R., Reilly-O’Donnell, B., Catapano, F., Faggian, G. G., Gorelik, J., Martelli, F., & Emanueli, C. (2020) · Cells · doi:10.3390/cells9030592 · Cited by 60
miR-21, Mediator, and Potential Therapeutic Target in the Cardiorenal Syndrome
Huang, C.-K., Bär, C., & Thum, T. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00726 · Cited by 66
Self-citationTargeted Therapy in Cardiovascular Disease: A Precision Therapy Era
Xu, M., Zhang, K., & Song, J. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.623674 · Cited by 61
Ouyang, H., He, X., Li, G., Xu, H., Jia, X., Nie, Q., & Zhang, X. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms160716242 · Cited by 62
“Among these miRNAs, miR-21 was found to be highly expressed in many species, and associated with cardiac disease and a wide variety of human cancers [44,45].”
BackgroundCirculating MicroRNAs as Novel Biomarkers for the Early Diagnosis of Acute Coronary Syndrome
Deddens, J. C., Colijn, J. M., Oerlemans, M. I. F. J., Pasterkamp, G., Chamuleau, S. A. J., Doevendans, P. A., & Sluijter, J. P. G. (2013) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-013-9493-9 · Cited by 65
Clinical use of novel biomarkers in heart failure: towards personalized medicine
Schmitter, D., Cotter, G., & Voors, A. A. (2013) · Heart Failure Reviews · doi:10.1007/s10741-013-9396-5 · Cited by 58
MicroRNAs in Diabetic Kidney Disease
Li, R., Chung, A. C. K., Yu, X., & Lan, H. Y. (2014) · International Journal of Endocrinology · doi:10.1155/2014/593956 · Cited by 60
“As phosphatase and tensin homolog (PTEN) is one of potential targets of miR21 [71, 72], upregulation of Akt pathway may be another mechanism for miR-21 to participate in diabetic kidney injury.”
BackgroundIwamoto, N., Vettori, S., Maurer, B., Brock, M., Pachera, E., Jüngel, A., Calcagni, M., Gay, R. E., Whitfield, M. L., Distler, J. H. W., et al. (2014) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2014-205326 · Cited by 55
Chen, Y., Wakili, R., Xiao, J., Wu, C.-T., Luo, X., Clauß, S., Dawson, K., Qi, X., Naud, P., Shi, Y., et al. (2014) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2014.10.001 · Cited by 55
Heart Failure: Advanced Development in Genetics and Epigenetics
Yang, J., Xu, W., & Hu, S. (2015) · BioMed Research International · doi:10.1155/2015/352734 · Cited by 60
“found that an antimiR functionally designed to inhibit miR-21 significantly reversed the progression of cardiac hypertrophy and fibrosis and attenuated the impairment of cardiac function [104].”
Holding Our Breath: The Emerging and Anticipated Roles of microRNA in Pulmonary Hypertension
White, K., Loscalzo, J., & Chan, S. Y. (2012) · Pulmonary Circulation · doi:10.4103/2045-8932.101395 · Cited by 58
“Notably, miR-21 is an established molecular regulator in the pathogenesis of many human diseases,[64] including cancer and cardiovascular diseases, such as cardiac fibrosis and heart failure,[65] aortic aneurysm development,[66] and peripheral vascular remodeling.”
Background
Metadata
- Authors
- Thum, T., Gross, C., Fiedler, J., Fischer, T., Kissler, S., Bussen, M., Galuppo, P., Just, S., Rottbauer, W., Frantz, S., Castoldi, M., Soutschek, J., Koteliansky, V., Rosenwald, A., Basson, M. A., Licht, J. D., Pena, J. T. R., Rouhanifard, S. H., Muckenthaler, M. U., Tuschl, T., Martin, G. R., Bauersachs, J., & Engelhardt, S.
- Affiliations
- University of Würzburg (DE)
- Deutsche Forschungsgemeinschaft (DE)
- University of California, San Francisco (US)
- Heidelberg University (DE)
- Regulus Therapeutics (United States) (US)
- Alnylam Pharmaceuticals (United States) (US)
- King's College London (GB)
- Northwestern University (US)
- Rockefeller University (US)
- Technical University of Munich (DE)
- Corresponding author
- Bauersachs, Johann
- Engelhardt, Stefan
- ORCID
- Thum, Thomas
- Gross, Carina
- Fiedler, Jan
- Fischer, Thomas
- Kissler, Stephan
- Galuppo, Paolo
- Just, Steffen
- Rottbauer, Wolfgang
- Frantz, Stefan
- Castoldi, Mirco
- Rosenwald, Andreas
- Basson, M. Albert
- Licht, Jonathan D.
- Pena, John T. R.
- Rouhanifard, Sara H.
- Muckenthaler, Martina U.
- Tuschl, Thomas
- Bauersachs, Johann
- Engelhardt, Stefan
- Venue
- Nature
- Published
- 2008-11-30
- Volume
- 456
- Issue
- 7224
- Pages
- 980-984
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2132093971
- Cited by
- 2,349
- References
- 30
- Citations by year
- 2026: 62 · 2025: 70 · 2024: 71 · 2023: 76 · 2022: 106 · 2021: 131 · 2020: 151 · 2019: 138 · 2018: 153 · 2017: 167 · 2016: 150 · 2015: 200 · 2014: 183 · 2013: 203 · 2012: 176
- FWCI
- 75.20
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Research Portal (King's College London) (submittedVersion)
- mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
- Funders
- National Cancer Institute (R01CA078711, R01 CA 78711, R01CA059998)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Fibrosis and Remodeling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Congenital heart defects research
- Keywords
- miR-21, cardiac fibroblasts, heart failure, SPRY1, interstitial fibrosis, cardiac hypertrophy, microRNA silencing, antagomir, fibroblast survival, therapeutic target, cardiomyocytes
- MeSH terms
- Animals, Cell Line, Cell Survival, Cells, Cultured, Disease Models, Animal, Fibroblasts, Humans, Male, Mice, Transgenic, Cardiomyopathies, Gene Silencing, MAP Kinase Signaling System, Myocytes, Cardiac, MicroRNAs, Extracellular Signal-Regulated MAP Kinases, Mice, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.